Studies have demonstrated that the recovery of the repair ability in the muscle of patients having dysferlin deficiency when the muscles were treated with acid sphingomyelinase (ASM) and suggested that the ASM could also be a potential therapy for dysferlinopathy [8]. This evidence concerns the gene SMPD1 and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.